Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.11
+0.16005.42%
Post-market: 3.110.00000.00%19:52 EDT
Volume:6.16M
Turnover:19.39M
Market Cap:603.34M
PE:-4.09
High:3.24
Open:2.98
Low:2.95
Close:2.95
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:1.23
T/O Rate:3.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.27
PE(LYR):-3.11

Loading ...

Altimmune director John Gill buys 9,200 shares worth $31,348

Reuters
·
Apr 07

Altimmune CFO Gregory Weaver acquires $31,499 common shares

Reuters
·
Apr 02

Altimmune CEO Jerome Durso acquires $0.0 million common shares

Reuters
·
Apr 02

Altimmune Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Mar 19

Truist Initiates Altimmune at Buy With $12 Price Target

MT Newswires Live
·
Mar 19

U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKesson

Reuters
·
Mar 19

Altimmune initiated with a Buy at Truist

TIPRANKS
·
Mar 19

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

GlobeNewswire
·
Mar 18

Altimmune Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 17

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

GlobeNewswire
·
Mar 12

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

GlobeNewswire
·
Mar 09

Altimmune Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Mar 07

B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating

MT Newswires Live
·
Mar 06

Altimmune Inc. Announces 2026 Annual Stockholders Meeting

Reuters
·
Mar 06

Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Dow Jones
·
Mar 06

Altimmune Shares Fall After Q4 Results

MT Newswires Live
·
Mar 06

BUZZ-Altimmune falls after posting quarterly revenue below estimates

Reuters
·
Mar 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)

TIPRANKS
·
Mar 06

Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY

Benzinga Earnings
·
Mar 05

Altimmune Q4 revenue beats, EPS misses estimates

Reuters
·
Mar 05